Takeda Pharmaceutical shares rebounded on August 18, rising 189 yen from the previous day to 5,702 yen, nearly recovering the decline that followed its earnings announcement. In the first quarter of fiscal 2027, revenue rose 10.2% year on year to 1.2199 trillion yen, and operating profit increased 9.1% to 201.4 billion yen, while net profit attributable to owners of the parent fell 8.9% to 113.2 billion yen. The main reason for the profit decline was that corporate income tax expenses swelled 87.7% to 49.5 billion yen, affected by a reassessment of the recoverability of deferred tax assets and additional tax burdens under US international tax rules. The company also reported non-IFRS measures, with core operating profit up 11.5% to 358.9 billion yen and core EPS of 154 yen.
Takeda Pharmaceutical Co. Ltd.Revenue and operating profit grew but net profit fell 8.9% due to higher tax expenses, with shares rebounding after initial decline.
